ENHANCING PRIVATE EQUITY ACCOUNTING FRAMEWORKS IN INSURANCE COMPANIES
DOI:
https://doi.org/10.55640/Keywords:
Private equity, Insurance accounting, Fair value measurement, Risk management, IFRS 17, Regulatory complianceAbstract
This study aims to identify key deficiencies in current private equity accounting practices within insurance companies and propose enhanced frameworks that improve accuracy, transparency, and regulatory compliance while supporting strategic investment decisions.
Downloads
References
1.Anderson, J. M., & Martinez, C. R. (2022). Strategic asset allocation in insurance companies: The role of alternative investments. Journal of Insurance Economics, 45(3), 234-251.
2.Chen, L., & Rodriguez, M. A. (2021). IFRS 9 implementation challenges for insurance companies: Private equity and alternative investments. International Accounting Review, 38(4), 412-429.
3.Davies, P. K., & Kim, S. H. (2023). IFRS 17 implications for asset-liability management in insurance companies. Insurance Accounting Quarterly, 29(2), 78-95.
4.International Private Equity and Venture Capital Valuation Board. (2022). International Private Equity and Venture Capital Valuation Guidelines (December 2022 Edition). IPEV Board.
5.Lee, R. T., Williams, J. P., & Thompson, A. M. (2023). Valuation practices in private equity: A comparative analysis of insurance company approaches. Alternative Investment Research, 31(1), 156-174.
6.Thompson, B. C., Zhang, Y., & O'Connor, D. M. (2023). Regulatory capital requirements and private equity investment strategies in insurance companies. Risk Management Journal, 48(2), 89-107.
7.Williams, K. L., & Johnson, E. R. (2022). Fair value measurement challenges in private equity: Evidence from insurance company portfolios. Financial Reporting Standards Review, 19(3), 203-221.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
